GVR Report cover Antacids Market Size, Share & Trends Report

Antacids Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Liquid), By Distribution Channel (Retail, Hospital, Online Pharmacy), By Region (APAC, Europe, North America), And Segment Forecasts, 2019 - 2025

  • Published Date: Jan, 2019
  • Base Year for Estimate: 2017
  • Report ID: GVR-2-68038-693-6
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016
  • Number of Pages: 90

Industry Insights

The global antacids market size was valued at USD 5.83 billion in 2017 and is projected to expand at a CAGR of 3.9% over the forecast period. Changing dietary habits is one of the major factors expected to fuel growth during the forecast period.

Increasing prevalence of Gastro-Esophageal Reflux Diseases (GERD) is expected to affect the overall market over the forecast period. According to the Gut journal, published by the International Foundation for Gastrointestinal Disorders; in 2017, the prevalence of GERD was around 18% to 28% in North America, 9% to 26% in Europe, 3% to 8% in East Asia, 9% to 33% in the Middle East, 12% in Australia, and 23% in South America.

U.S. antacids market

Furthermore, increasing awareness about GERD is anticipated to boost the antacids market. According to an article published in the International Foundation for Gastrointestinal Disorders, the 19th Annual GERD Awareness Week was in November 2018 which provided information and support regarding this condition. Also, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) encourages patients suffering from GERD-related symptoms, to consult their physicians.

Also, the increasing prevalence of heartburn is estimated to affect the market over the forecast period. According to an article published in the Medical Xpress, a web-based medical and health news service; in 2017, researchers from the University of Michigan identified that acid reflux and heartburn affected more than 20% of the U.S. population.

Dosage Form Insights

Tablet was estimated to be the largest segment in 2017. The presence of chewable tablets in different flavors helps improve patient adherence to the medication, which in turn is expected to contribute to the growth of the segment. Tablets can provide the exact amount of dosage to the patients compared to other dosage forms and they are easy to store. These factors can be attributed to the segment growth over the forecast period. Other key drivers expected to facilitate the segment growth include the launch of new products by major players.

The liquid segment is expected to be the fastest-growing segment in the overall market during the forecast period. Presence of key players, such as Pfizer Inc.; GlaxoSmithKline plc. and Dabur offering liquid antacid is estimated to boost the segment growth. Also, the liquid dosage form is one of the favored choices for children and the elderly population due to its palatable taste. This factor is also anticipated to bode well for market growth.

Distribution Channel Insights

Based on the distribution channel, the market is trifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. In 2017, retail pharmacy held the largest market share due to the easy accessibility and availability of these pharmacies. For instance, MedPlus has around 1,400 outlets out of which 1,350 are self-owned and rest are taken as a franchisee.

Online pharmacy is estimated to be the fastest-growing segment over the forecast period owing to increasing awareness among consumers. According to a survey conducted by the Alliance For Safe Online Pharmacies (ASOP Global) in 2017, 33% of survey participants from Canada had purchased prescription medicines from an online pharmacy.

Global antacids market

People are opting for online pharmacies owing to lucrative offers, such as price discounts, ease in availability of drugs, and home delivery services. Also, the growing adoption of information technology in the healthcare sector is enabling clinicians to send prescriptions electronically, which is expected to boost growth.

Regional Insights

The Asia Pacific is expected to be the largest and fastest-growing regional segment during the forecast period owing to high unmet clinical needs, availability of effective treatment methods, rising disposable income, and consumer awareness about the availability of these products. Besides, the presence of key players, such as GlaxoSmithKline plc.; Pfizer Inc.; Abbott is anticipated to grow the market over the forecast period. Improving healthcare infrastructure, and growing investments by market players are expected to increase its growth.

North America is estimated to be the second-largest growing segment. This was attributed to increasing digestive disorder prevalence coupled with consumer awareness of antacid products. In 2017, according to the CDC, the number of visits to emergency departments with digestive system diseases as the primary diagnosis was around 32.3 million. Furthermore, the presence of developed economies within the region is adding fuel to its growth in this region.

Antacids Market Share Insights

The overall market is likely to face intense competition over the forecast period owing to the presence of multinational players and small-scale companies. Geographical expansion and joint ventures are some of the key strategies undertaken by key players in the market. For instance, in 2016, Takeda Pharmaceutical Company Limited launched first and approved proton pump inhibitor, Dexilant (Dexlansoprazole), which uses dual delayed-release technology for patients with GERD.

Some of the key players are GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy’s Laboratories Ltd.; Sanofi; Reckitt Benckiser Group plc; Sun Pharmaceuticals Ltd.; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.

Report Scope



The base year for estimation


Actual estimates/Historical data

2014 - 2016

Forecast period

2018 - 2025

Market representation

Revenue in USD Million & CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Country Scope

U.S., Canada, U.K., Germany, Mexico, Brazil, Japan, China, India, South Africa

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research, Inc. has segmented the global antacids market report based on dosage form, distribution channel, and region:

  • Dosage Form Outlook (Revenue, USD Million, 2014 - 2025)

    • Tablet

    • Liquid

    • Others

  • Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)

    • Retail Pharmacy

    • Hospital Pharmacy

    • Online Pharmacy

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.